MRNA Tripled. Now It Has a $2.6B Offering.
Moderna’s Phase 3 melanoma win was historic. Days later, a convertible note deal is the real question investors must answer.
August 29, 2026
America’s Forgotten Energy Reserve
August 29, 2026 Bonus Content: Gilead’s Bixlenvo Is Approved. Now the Switch Math Begins. Sponsored Dear Reader, On a single…
ROIV Has Its First Approval. Now Comes the Harder Part.
Lisraya wins dermatomyositis, but a boxed warning, a larger patient pool than advertised, and Phase 3 readouts define what the stock is actually worth.
In at 9:35 AM. Out by 10.
August 29, 2026 Bonus Content: The IPO Window Is Open. Now the Fed May Slam It. Sponsored Hey, I’m going…